$21.10
3.08% yesterday
Nasdaq, May 20, 10:03 pm CET
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

AnaptysBio, Inc. Stock price

$21.10
+0.48 2.33% 1M
+0.79 3.89% 6M
+7.86 59.37% YTD
-3.91 15.63% 1Y
+0.22 1.05% 3Y
+1.45 7.38% 5Y
+4.10 24.12% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.63 3.08%
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

Key metrics

Market capitalization $619.93m
Enterprise Value $625.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.60
P/S ratio (TTM) P/S ratio 5.54
P/B ratio (TTM) P/B ratio 18.85
Revenue growth (TTM) Revenue growth 387.20%
Revenue (TTM) Revenue $111.87m
EBIT (operating result TTM) EBIT $-100.29m
Free Cash Flow (TTM) Free Cash Flow $-102.31m
Cash position $339.94m
EPS (TTM) EPS $-4.84
P/E forward negative
P/S forward 9.15
EV/Sales forward 9.24
Short interest 55.05%
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a AnaptysBio, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
75%
Hold
25%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
112 112
387% 387%
100%
- Direct Costs 2.40 2.40
0% 0%
2%
109 109
432% 432%
98%
- Selling and Administrative Expenses 40 40
2% 2%
36%
- Research and Development Expense 167 167
25% 25%
150%
-98 -98
36% 36%
-88%
- Depreciation and Amortization 2.40 2.40
0% 0%
2%
EBIT (Operating Income) EBIT -100 -100
35% 35%
-90%
Net Profit -141 -141
14% 14%
-126%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Neutral
GlobeNewsWire
15 days ago
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
about 2 months ago
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share.
Neutral
GlobeNewsWire
3 months ago
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45...
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 136
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today